Health Catalyst Reports $178M Net Loss Driven by $105M Goodwill Impairment, Announces Further Workforce Reductions and Significant Cash Burn
HCAT is trading near its 52-week low of $1.56 (2.6% below the low).
Summary
Health Catalyst reported a significantly widened net loss of $178.0 million for 2025, largely due to a $105.4 million goodwill impairment. The company also experienced a sharp decline in cash, implemented further workforce reductions, and anticipates future revenue headwinds.
Key Events · Earnings and Guidance · HCAT
-
Significant Net Loss Reported
The company reported a net loss of $178.0 million for the year ended December 31, 2025, a substantial increase from $69.5 million in 2024.
-
Major Goodwill Impairment Charge
A non-cash goodwill impairment charge of $105.4 million was recognized in 2025, primarily due to declines in stock price and market capitalization.
-
Substantial Decline in Cash
Cash and cash equivalents decreased significantly from $249.6 million at the end of 2024 to $50.8 million at the end of 2025.
-
Multiple Workforce Reductions
The company executed two additional restructuring plans in January and August 2025, reducing the global workforce by 4% and 9% respectively, following a 10% reduction in late 2023/early 2024.
Analysis · HCAT · Technology
Health Catalyst, Inc. reported a substantial net loss of $178.0 million for the year ended December 31, 2025, a significant widening from the $69.5 million loss in 2024. This increased loss was primarily driven by a non-cash goodwill impairment charge of $105.4 million, indicating a re-evaluation of the value of past acquisitions and a challenging outlook. The company's cash and cash equivalents plummeted from $249.6 million in 2024 to $50.8 million in 2025, reflecting substantial cash burn. Furthermore, Health Catalyst implemented two additional workforce reductions in January and August 2025, following a prior restructuring in 2023, underscoring ongoing efforts to optimize costs amid a difficult macroeconomic environment and policy changes like the 'One Big Beautiful Bill Act' impacting Medicaid funding. These factors, combined with anticipated revenue headwinds from client migrations and churn, paint a challenging picture for the company's financial performance in the near term.
At the time of this filing, HCAT was trading at $1.52 on NASDAQ in the Technology sector, with a market capitalization of approximately $126.6M. The 52-week trading range was $1.56 to $5.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.